Patents by Inventor Daniel HOG

Daniel HOG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PTEFB inhibiting macrocyclic compounds
    Patent number: 11691986
    Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: July 4, 2023
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Daniel Hog, Clara Christ, Ulrike Sack, Franziska Siegel, Philip Lienau, Nicolas Werbeck
  • NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS
    Publication number: 20220281892
    Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: January 12, 2022
    Publication date: September 8, 2022
    Inventors: Ulrich LÜCKING, Daniel HOG, Clara CHRIST, Ulrike SACK, Franziska SIEGEL, Philip LIENAU, Nicolas WERBECK
  • PTEFB INHIBITING MACROCYCLIC COMPOUNDS
    Publication number: 20220267353
    Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: December 21, 2021
    Publication date: August 25, 2022
    Inventors: Ulrich LÜCKING, Daniel HOG, Clara CHRIST, Ulrike SACK, Franziska SIEGEL, Philip LIENAU, Nicolas WERBECK
  • PTEFb inhibiting macrocyclic compounds
    Patent number: 11254690
    Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: February 22, 2022
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Daniel Hog, Clara Christ, Ulrike Sack, Franziska Siegel, Philip Lienau, Nicolas Werbeck
  • PTEFb inhibiting macrocyclic compounds
    Patent number: 11242356
    Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: February 8, 2022
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Daniel Hog, Clara Christ, Ulrike Sack, Franziska Siegel, Philip Lienau, Nicolas Werbeck
  • NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS
    Publication number: 20200347079
    Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: March 22, 2018
    Publication date: November 5, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich LÜCKING, Daniel HOG, Clara CHRIST, Ulrike SACK, Franziska SIEGEL, Philip LIENAU, Nicolas WERBECK
  • Macrocyclic sulfondiimine compounds
    Patent number: 10717749
    Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: July 21, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Jens Geisler, Daniel Hog, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Kunzeng Zheng, Ping Gao, Gang Chen, Jiajun Xi, Simon Anthony Herbert, Gerhard Siemeister, Nicolas Werbeck
  • NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS
    Publication number: 20200123174
    Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: March 22, 2018
    Publication date: April 23, 2020
    Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Daniel Hog, Clara Christ, Ulrike Sack, Franziska Siegel, Philip Lienau, Nicolas Werbeck
  • Modified macrocyclic compounds
    Patent number: 10214542
    Abstract: The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: February 26, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Daniel Hog, Jens Geisler, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Gerhard Siemeister, Nicolas Werbeck
  • NOVEL MODIFIED MACROCYCLIC COMPOUNDS
    Publication number: 20180282346
    Abstract: The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: September 30, 2016
    Publication date: October 4, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich LÜCKING, Daniel HOG, Jens GEISLER, Arne SCHOLZ, Kirstin PETERSEN, Philip LIENAU, Christian STEGMANN, Dorothee ANDRES, Gerhard SIEMEISTER, Nicolas WERBECK
  • NOVEL MACROCYCLIC SULFONDIIMINE COMPOUNDS
    Publication number: 20180273548
    Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: September 26, 2016
    Publication date: September 27, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich LÜCKING, Jens GEISLER, Daniel HOG, Arne SCHOLZ, Kirstin PETERSEN, Philip LIENAU, Christian STEGMANN, Dorothee ANDRES, Kunzeng ZHENG, Ping GAO, Gang CHEN, Jiajun XI, Simon Anthony HERBERT, Gerhard SIEMEISTER, Nicolas WERBECK